Current and future role of MR enterography in the management of Crohn disease

American Journal of Roentgenology

Volumn 201, Issue 1, 2013, Pages 56-64

  Makanyanga, Jesica C ^a   Taylor, Stuart A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Crohn disease; Disease activity; MR enterography

Indexed keywords

CLINICAL ASSESSMENT; CLINICAL FEATURE; COLON MOTILITY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; ENDOSCOPY; ENTEROGRAPHY; HARVEY BRADSHAW INDEX; HUMAN; INTESTINE BIOPSY; INTESTINE RADIOGRAPHY; MAGNETIC RESONANCE ENTEROGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM;

CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING;

EID: 84883331434     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.10406     Document Type: Review

References (77)

1. Louis E, Collard A, Oger A, Degroote E. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49:777-782
2. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8:244-250
3. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105:289-297
4. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-1395
5. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371:660-667
6. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011; 17:1415-1422
7. Pariente B, Peyrin-Biroulet L, Cohen L, Zagdanski AM, Colombel JF. Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. AJR 2011; 197:42-49
8. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7:874-881
9. Keane J, Gershon S. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-1104
10. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53:849-853
11. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126:19-31
12. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-444
13. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1:514
14. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122:512-530
15. Gomes P, Du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27:92-95
16. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease: a prospective multicentre study of 121 cases. Gut 1994; 35:231-235
17. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11:707-712
18. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2009; 105:162-169
19. Regueiro M, Kip KE, Schraut W, et al. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011; 17:118-126
20. Vermeire S. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:661-665
21. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55:426-431
22. Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34:50-54
23. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30:983-989
24. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60:505-512
25. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956-963
26. Siddiki H, Fidler J. MR imaging of the small bowel in Crohn's disease. Eur J Radiol 2009; 69:409-417
27. Fidler J. MR imaging of the small bowel. Radiol Clin North Am 2007; 45:317-331
28. Masselli G, Gualdi G. MR imaging of the small bowel. Radiology 2012; 264:333-348
29. Bakir B, Acunas B, Bugra D, et al. MR colonography after oral administration of polyethylene glycol-electrolyte solution. Radiology 2009; 251:901-909
30. Ajaj W, Pelster G, Treichel U, Vogt F. Dark lumen magnetic resonance colonography: comparison with conventional colonoscopy for the detection of colorectal pathology. Gut 2003; 52:1738-1743
31. Ajaj WM, Lauenstein TC, Pelster G, et al. Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. Gut 2005; 54:257-263
32. Friedrich C, Fajfar A, Pawlik M, et al. Magnetic resonance enterography with and without biphasic contrast agent enema compared to conventional ileocolonoscopy in patients with Crohn's disease. Inflamm Bowel Dis 2012; 18:1842-1848
33. Makanyanga J, Punwani S. Taylor SA. Assessment of wall inflammation and fibrosis in Crohn's disease: value of T1-weighted gadolinium-enhanced MR imaging. Abdom Imaging 2012; 37:933-943
34. Florie J, Wasser MN Arts-Cieslik K, Akkerman EM, Siersema PD, Stoker J. Dynamic contrastenhanced MRI of the bowel wall for assessment of disease activity in Crohn's disease. AJR 2006; 186:1384-1392
35. Ziech ML, Bipat S, Roelofs J, et al. Retrospective comparison of magnetic resonance imaging features and histopathology in Crohn's disease patients. Eur J Radiol 2010; 80:e299-e305
36. Ziech MLW, Lavini C, Caan MW, et al. Dynamic contrast-enhanced MRI in patients with luminal Crohn's disease. Eur J Radiol 2012; 81:3019-3027
37. Taylor SA, Punwani S, Rodriguez-Justo M, et al. Mural Crohn disease: correlation of dynamic contrast-enhanced MR imaging findings with angiogenesis and inflammation at histologic examination-pilot study. Radiology 2009; 251:369-379
38. Maccioni F, Bruni A, Viscido A. MR imaging in patients with Crohn disease: value of T2-versus T1 weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology 2006; 238:517-530
39. Rimola J, Rodriguez S, García-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009; 58:1113-1120
40. Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn's disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis 2011; 17:984-993
41. Maccioni F, Staltari I, Pino AR, Tiberti A. Value of T2-weighted magnetic resonance imaging in the assessment of wall inflammation and fibrosis in Crohn's disease. Abdom Imaging 2012; 37:944-957
42. Kiryu S, Dodanuki K, Takao H, et al. Freebreathing diffusion-weighted imaging for the assessment of inflammatory activity in Crohn's disease. J Magn Reson Imaging 2009; 29:880-886
43. Oto A, Zhu F, Kulkarni K, Karczmar GS, Turner JR, Rubin D. Evaluation of diffusion-weighted MR imaging for detection of bowel inflammation in patients with Crohn's disease. Acad Radiol 2009; 16:597-603
44. Oto A, Kayhan A, Williams JT, et al. Active Crohn's disease in the small bowel: evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. J Magn Reson Imaging 2011; 33:615-624
45. Schmid-Tannwald C, Agrawal G, Dahi F, Sethi I, Oto A. Diffusion-weighted MRI: role in detecting abdominopelvic internal fistulas and sinus tracts. J Magn Reson Imaging 2012; 131:125-131
46. Oussalah A, Laurent V, Bruot O, et al. Diffusionweighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut 2010; 59:1056-1065
47. Froehlich JM, Waldherr C, Stoupis C, Erturk SM. Patak MA. MR motility imaging in Crohn's disease improves lesion detection compared with standard MR imaging. Eur Radiol 2010; 20:1945-1951
48. Menys A, Atkinson D, Odille F, et al. Quantified terminal ileal motility during MR enterography as a potential biomarker of Crohn's disease activity: a preliminary study. Eur Radiol 2012; 22:2494-2501
49. Adler J, Swanson SD, Mckenna BJ, Verrot TM, Zimmermann EM. Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease. Radiology 2011; 259:127-135
50. Adler J, Al-Hawary MM, Dillman JR, et al. Magnetization transfer MRI for in vivo imaging bowel fibrosis in patients with Crohn's disease. (abstract) Gastroenterology 2010; 138:S359
51. Sailer J, Peloschek P, Reinisch W, Vogelsang H, Turetschek K, Schima W. Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol 2008; 18:2512-2521
52. Rimola J, Ordás I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011; 17:1759-1768
53. Steward MJ, Punwani S, Proctor I, et al. Nonperforating small bowel Crohn's disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index. Eur J Radiol 2012; 81:2080-2088
54. Horsthuis K, Bipat S, Stokkers PC, Stoker J. Magnetic resonance imaging for evaluation of disease activity in Crohn's disease: a systematic review. Eur Radiol 2009; 19:1450-1460
55. Bruining DH. Siddiki HA, Fletcher JG, Tremaine WJ, Sandborn WJ, Loftus EV. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm Bowel Dis 2008; 14:1701-1706
56. Messaris E, Chandolias N, Grand D, Pricolo V. Role of magnetic resonance enterography in the management of Crohn disease. Arch Surg 2010; 145:471-475
57. Hafeez R, Punwani S, Boulos P, et al. Diagnostic and therapeutic impact of MR enterography in Crohn's disease. Clin Radiol 2011; 66:1148-1158
58. Zippi M, Al Ansari N, Siliquini F, et al. Correlation between magnetic resonance imaging (MRI) and faecal calprotectin in Crohn's disease. (abstract) Ital J Med 2012; 6(suppl 1):151
59. Makanyanga J, Pendse D, Atkins E, et al. Magnetic resonance imaging is correlated with faecal calprotectin level in the evaluation of small bowel and colonic Crohn's disease (abstract B-0058). European Society of Radiology Interactive Programme Planner website. http://ipp.myesr.org/esr/ecr20 Accessed March 5, 2013
60. Arnott ID, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther 2002; 16:857-867
61. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63:433-442
62. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15:1295-1301
63. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138:463-468
64. Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohn's Colitis 2012; 6(suppl 2):S224-S234
65. Travis S, Feagan BG, Rutgeerts P, Van Deventer S. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. J Crohns Colitis 2012; 6(suppl 2):S250-S259
66. Siddiki HA, Fidler JL, Fletcher JG, et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR 2009; 193:113-121
67. Samuel S, Bruining DH, Loftus EV, et al. Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol 2012; 10:1253-1259
68. D'Haens GR, Fedorak R, Lémann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis 2009; 15:1599-1604
69. French H. Mark Dalzell A, Srinivasan R, El-Matary W. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn's disease: a meta-analysis. Dig Dis Sci 2011; 56:1929-1936
70. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142:63-70
71. D'Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106:199-212
72. Ordàs I, Rimola J, Ripolles T, et al. Accuracy of MRI to assess therapeutic responses and mucosal healing in Crohn's disease. Gastroenterology 2011; 140(suppl 1):S73
73. Van Assche GA. Hermann KA, Louis E, et al. Effects of infliximab therapy on transmural lesions assessed by MRI enteroclysis in patients with ileal Crohn's disease: the ACTIF study. Gastroenterology 2011; 140(suppl 1):S73
74. Tielbeek J, Lowenberg M, Stoker J. Serial MRI reveals reduction of inflammation and improvement of stenosis in small bowel Crohn's disease treated with anti-TNF antibodies. Gastroenterology 2012; 142(suppl 1):S340
75. Lasocki A, Pitman A, Williams R, Lui B, Kalade AV, Farish S. Relative efficacy of different MRI signs in diagnosing active Crohn's disease, compared against a histological gold standard. J Med Imaging Radiat Oncol 2011; 55:11-19
76. Koh DM, Miao Y, Chinn R, et al. MR imaging evaluation of the activity of Crohn's disease. AJR 2001; 177:1325-1332
77. Gourtsoyiannis N, Papanikolaou N, Grammatikakis J, Papamastorakis G, Prassopoulos P, Roussomoustakaki M. Assessment of Crohn's disease activity in the small bowel with MR and conventional enteroclysis: preliminary results. Eur Radiol 2004; 14:1017-1024